[Our experience in the chemotherapy of urologic cancers and its complications].
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011374:Progesterone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D013852:Thiotepa / Q000627:therapeutic use; D014565:Urogenital Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D001761:Bleomycin; D003609:Dactinomycin; D011374:Progesterone; D014747:Vinblastine; D003520:Cyclophosphamide; D013852:Thiotepa; D008727:Methotrexate
Notre expérience de la chimiothérapie des cancers urologiques et de ses incidents